280.56 USD
-1.56
0.55%
At close Feb 14, 4:00 PM EST
After hours
280.56
+0.00
0.00%
1 day
-0.55%
5 days
-1.34%
1 month
5.06%
3 months
7.43%
6 months
46.48%
Year to date
9.23%
1 year
48.61%
5 years
32.14%
10 years
767.00%
 

About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Employees: 3,000

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

42% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 64

13% more capital invested

Capital invested by funds: $14.4B [Q2] → $16.4B (+$1.92B) [Q3]

3% more funds holding

Funds holding: 589 [Q2] → 609 (+20) [Q3]

5% less repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 232

1.46% less ownership

Funds ownership: 102.17% [Q2] → 100.72% (-1.46%) [Q3]

29% less call options, than puts

Call options by funds: $163M | Put options by funds: $229M

75% less funds holding in top 10

Funds holding in top 10: 8 [Q2] → 2 (-6) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$304
8%
upside
Avg. target
$315
12%
upside
High target
$330
18%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
TD Cowen
Joshua Jennings
48% 1-year accuracy
10 / 21 met price target
15%upside
$324
Buy
Maintained
3 Jan 2025
JP Morgan
Robbie Marcus
65% 1-year accuracy
13 / 20 met price target
18%upside
$330
Overweight
Maintained
12 Dec 2024
Citigroup
Joanne Wuensch
66% 1-year accuracy
31 / 47 met price target
10%upside
$310
Buy
Maintained
11 Dec 2024
Wells Fargo
Lawrence Biegelsen
67% 1-year accuracy
2 / 3 met price target
9%upside
$305
Overweight
Maintained
11 Dec 2024
Canaccord Genuity
William Plovanic
71% 1-year accuracy
35 / 49 met price target
8%upside
$304
Buy
Maintained
9 Dec 2024

Financial journalist opinion

Based on 3 articles about PODD published over the past 30 days

Positive
Zacks Investment Research
2 days ago
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Positive
Zacks Investment Research
2 weeks ago
NVIDIA & 2 Other Profitable Stocks to Buy in February
NVIDIA, AppLovin and Insulet have been selected as the top picks with a high net income ratio.
NVIDIA & 2 Other Profitable Stocks to Buy in February
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Add PODD Stock to Your Portfolio Now
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
Here's Why You Should Add PODD Stock to Your Portfolio Now
Positive
Zacks Investment Research
1 month ago
GEHC or PODD: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
GEHC or PODD: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
1 month ago
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
Neutral
Business Wire
1 month ago
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for.
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
Neutral
Business Wire
1 month ago
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available.
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Positive
Investors Business Daily
1 month ago
Insulin Device Maker Has Analysts Turning Bullish
Insulet stock is near a buy point after gapping up on earnings. The company increased its full year sales guidance.
Insulin Device Maker Has Analysts Turning Bullish
Positive
Zacks Investment Research
1 month ago
GEHC vs. PODD: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?
GEHC vs. PODD: Which Stock Is the Better Value Option?
Positive
FXEmpire
1 month ago
Heavy Interest in Insulet's Insulin Delivery Device
Sales are surging for Insulet Corporation (PODD).
Heavy Interest in Insulet's Insulin Delivery Device
Charts implemented using Lightweight Charts™